VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ISA 2022 | The promise of CRISPR-based gene editing therapy for hATTR amyloidosis

Marcus Anthony Urey, MD, University of California, San Diego, CA, talks on the potential of CRISPR-based gene-editing therapy for patients with hereditary transthyretin-mediated (hATTR) amyloidosis. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultancy: Alnylam, Akcea, BridgeBio
Honoraria: Pfizer
Research support: Ionis

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter